At the end of the latest market close, Takeda Pharmaceutical Company Limited (TAK) was valued at $14.22. In that particular session, Stock kicked-off at the price of $14.25 while reaching the peak value of $14.27 and lowest value recorded on the day was $14.03. The stock current value is $14.10.Recently in News on October 7, 2021, FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance. − If approved by the FDA, maribavir will be the first and only treatment indicated for adults in this patient population. You can read further details here
Takeda Pharmaceutical Company Limited had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $19.97 on 03/22/21, with the lowest value was $14.03 for the same time period, recorded on 10/12/21.
Takeda Pharmaceutical Company Limited (TAK) full year performance was -21.19%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Takeda Pharmaceutical Company Limited shares are logging -29.38% during the 52-week period from high price, and -0.07% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $14.11 and $19.97.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 4514114 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Takeda Pharmaceutical Company Limited (TAK) recorded performance in the market was -22.53%, having the revenues showcasing -18.31% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 45.26B, as it employees total of 47099 workers.
Takeda Pharmaceutical Company Limited (TAK) in the eye of market guru’s
During the last month, 0 analysts gave the Takeda Pharmaceutical Company Limited a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 16.69, with a change in the price was noted -3.22. In a similar fashion, Takeda Pharmaceutical Company Limited posted a movement of -18.59% for the period of last 100 days, recording 2,067,029 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for TAK is recording 0.84 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.84.
Takeda Pharmaceutical Company Limited (TAK): Stocks Technical analysis and Trends
Raw Stochastic average of Takeda Pharmaceutical Company Limited in the period of last 50 days is set at 2.13%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 2.13%. In the last 20 days, the company’s Stochastic %K was 3.32% and its Stochastic %D was recorded 4.96%.
If we look into the earlier routines of Takeda Pharmaceutical Company Limited, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -22.53%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -17.35%, alongside a downfall of -21.19% for the period of the last 12 months. The shares increased approximately by -12.31% in the 7-day charts and went up by -16.96% in the period of the last 30 days. Common stock shares were lifted by -18.31% during last recorded quarter.